Nicox News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.10.20	Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis (GlobeNewswire)
24.09.20	BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SEVEN COUNTRIES (GlobeNewswire)
23.09.20	Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial (GlobeNewswire)
22.09.20	Nicox’s ZERVIATE Receives IND Approval in China (GlobeNewswire)
18.09.20	Nicox Announces Senior Management Change (GlobeNewswire)
10.09.20	Nicox First Half 2020 Financial Results and Business Update (GlobeNewswire)
02.09.20	Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trial (GlobeNewswire)
12.08.20	Nicox Partners ZERVIATE in the Gulf and Arab Markets (GlobeNewswire)
05.08.20	Nicox Negotiating €2 million Non-Dilutive Loans Guaranteed by the French State (GlobeNewswire)
05.08.20	Nicox: Implementation of a liquidity contract with Kepler Cheuvreux (GlobeNewswire)
31.07.20	Nicox Receives €5 Million Upon Closing of VISUfarma Divestment (GlobeNewswire)
17.07.20	Nicox Second Quarter 2020 Business Update and Financial Highlights (GlobeNewswire)
15.07.20	Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucoma (GlobeNewswire)
10.07.20	Nicox Partner Ocumension Completes Successful Hong Kong IPO at an approximately US$1,090 Million Valuation (GlobeNewswire)
10.07.20	Nicox Strengthens Cash Position With Divestment of its VISUfarma Shareholding (GlobeNewswire)
02.06.20	Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma (GlobeNewswire)
17.04.20	Nicox First Quarter 2020 Business Update and Financial Highlights (GlobeNewswire)
08.04.20	Nicox Outlines Plans to Progress NCX 4251 into Phase 2b Trial Following Positive Meeting with FDA (GlobeNewswire)
02.04.20	Nicox’s Partner Fera Pharmaceuticals Files Application for Orphan Drug Designation for Naproxcinod in Sickle-Cell Disease (GlobeNewswire)
31.03.20	Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States (GlobeNewswire)
11.03.20	Nicox Updates on ZERVIATE Progress in China and Expands the Countries of its Agreement with Ocumension Therapeutics (GlobeNewswire)
11.03.20	Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement (GlobeNewswire)
09.03.20	Nicox’s Partner Secures Additional Approval of VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan (GlobeNewswire)
06.03.20	Nicox Announces 2019 Financial Results and 2020 Key Milestones (GlobeNewswire)
05.03.20	Nicox’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma (GlobeNewswire)
03.02.20	Nicox Receives Formulation Patent Extending NCX 470 U.S. Patent Coverage to 2039 (GlobeNewswire)
21.01.20	Nicox Fourth Quarter 2019 Business Update and Financial Highlights (GlobeNewswire)
16.01.20	Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina (GlobeNewswire)
13.01.20	Nicox’s Partner Secures Approval of VYZULTA in Mexico (GlobeNewswire)
19.12.19	Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Disease (GlobeNewswire)
17.12.19	Nicox Draws Down Last Tranche from Bond Financing Agreement with Kreos Capital to Support Key Development Programs (GlobeNewswire)
06.12.19	Nicox signs agreement for ZERVIATE in South Korea (GlobeNewswire)
18.11.19	Nicox Raises €12.5 Million to Advance NCX 470 into Phase 3 in Glaucoma (GlobeNewswire)
22.10.19	Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucoma (GlobeNewswire)
16.10.19	Nicox: Third Quarter 2019 Business Update and Financial Highlights (GlobeNewswire)
10.10.19	Nicox Amends Bond Financing Agreement with Kreos and Draws Down Additional €4 Million (GlobeNewswire)
02.10.19	Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost (GlobeNewswire)
27.09.19	Nicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019 (GlobeNewswire)
17.09.19	Nicox: First Half 2019 Financial Results and Business Update (GlobeNewswire)
17.07.19	Nicox: Second Quarter 2019 Business Update and Financial Highlights (GlobeNewswire)
16.07.19	Nicox Announces Completion of Enrollment in NCX 470 Phase 2 Clinical Study with Top-Line Results on Track for Early 4Q 2019 (GlobeNewswire)
09.07.19	Nicox Receives $3 million Milestone Payment from Eyevance for ZERVIATE in the U.S. (GlobeNewswire)
02.07.19	Nicox signs agreement for NCX 4251 in China with Ocumension Therapeutics for up to €12 million in milestones plus royalties (GlobeNewswire)
06.05.19	Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019 (GlobeNewswire)
03.05.19	Nicox Presents First Data on Promising New Class of Nitric Oxide (NO)-Donating Compounds for Glaucoma at the ARVO 2019 Annual Meeting (GlobeNewswire)
29.04.19	Nicox to Present at Upcoming Pharmaceutical Industry and Financial Events (GlobeNewswire)
18.04.19	Nicox First Quarter 2019 Business Update and Financial Highlights (GlobeNewswire)
19.03.18	ShangPharma Innovation Expands Incubator to Drive Life Science Innovation in Bay Area (PR Newswire)
25.09.17	Diane Giard to speak at the CIBC Eastern Institutional Investor Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Kuehne+Nagel Int	203.20	0.30 %	K V
Alcon	76.40	0.10 %	K V
Lonza Grp	541.40	0.00 %	K V
Givaudan	4’060.00	-0.02 %	K V
Sonova Hldg	297.20	-0.03 %	K V
Swisscom	504.50	-0.49 %	K V
Swiss Re	131.00	-0.72 %	K V
Sika	224.40	-0.80 %	K V
Nestle	74.52	-0.93 %	K V
UBS Group	27.83	-1.21 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nicox SA provient regroupement

Aktien Top/Flop

Meistgelesene Nachrichten